RayzeBio, a subsidiary fully owned by Bristol-Myers Squibb (BMS), has recently announced the acquisition of global exclusive rights to develop, manufacture, and market Philochem AG's nuclear medicine product OncoACP3. The potential total transaction value for this deal could reach up to $1.35 billion. Under the terms of the agreement, Philochem will receive an initial payment of $350 million, with the potential for an additional $1 billion in milestones related to research and development, regulatory approvals, and commercialization. In other news, Canaan Inc. has successfully raised HK$864 million through a share placement. Within the realm of pharmaceutical R&D, Henlius Biotech has announced that its PD-L1 ADC HLX43 has completed the first patient dosing in an international, multicenter Phase II clinical trial for advanced non-small cell lung cancer, showing promising initial efficacy and safety results. Changshan Pharmaceutical has also clarified that the suspension of its abenatide's marketing approval is unrelated to any combined marketing approvals for weight loss products. Additionally, NVIDIA has forged a partnership with Novo Nordisk and the Danish AI Innovation Center to harness AI technology in order to expedite drug development processes.